Transient relief of metastatic cancer bone pain by oral administration of etidronate

Journal of Bone and Mineral Metabolism

Volumn 20, Issue 4, 2002, Pages 228-234

  Iwamoto, Jun ^a   Takeda, Tsuyoshi ^a   Ichimura, Shoichi ^b  

^a KEIO UNIVERSITY   (Japan)

^b NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

Bone metastasis; Bone pain; Cancer; Etidronate; Urinary cross linked N telopeptides of type I collagen (NTx)

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; ETIDRONIC ACID; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; ALKALINE PHOSPHATASE; ANALGESIC AGENT; BIOLOGICAL MARKER; COLLAGEN; COLLAGEN TYPE I TRIMERIC CROSS LINKED PEPTIDE; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; PEPTIDE;

ADULT; AGED; ANALGESIA; ANALYSIS OF VARIANCE; ARTICLE; BLADDER CANCER; BONE METASTASIS; BONE PAIN; BREAST CANCER; CANCER LOCALIZATION; CANCER PAIN; CLINICAL ARTICLE; COLON CANCER; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HYPERCALCEMIA; LUNG CANCER; MALE; OSTEOLYSIS; OUTPATIENT; PRIORITY JOURNAL; PROSTATE CANCER; STATISTICAL SIGNIFICANCE; STOMACH CANCER; TREATMENT OUTCOME; URINE LEVEL; BLOOD; BONE; BONE TUMOR; METASTASIS; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PAIN; PATHOPHYSIOLOGY;

ADMINISTRATION, ORAL; AGED; ALKALINE PHOSPHATASE; ANALGESICS, NON-NARCOTIC; BIOLOGICAL MARKERS; BONE AND BONES; BONE NEOPLASMS; COLLAGEN; COLLAGEN TYPE I; ETIDRONIC ACID; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PAIN; PEPTIDES;

EID: 0036050418     PISSN: 09148779     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007740200033     Document Type: Article

References (27)

1. Foley KM (1979) Pain syndromes in patients with cancer. In: Bonica JJ, Ventafridda V (eds) Advances in Pain Research and Therapy, Vol 2. Raven Press, New York, pp 59-76
2. Twycross RG (1979) Overview of analgesia. In: Bonica JJ, Ventafridda V (eds) Advances in Pain Research and Therapy, Vol 2. Raven Press, New York, pp 617-634
3. Diener KM (1996) Bisphosphonates for controlling pain from metastatic bone disease. Am J Health-Syst Pharm 53:1917-1927
4. Galasko CS (1976) Mechanisms of bone destruction in the development of skeletal metastasis. Nature 263:507-508
5. Iwamoto J, Takeda T, Ichimura S (2001) Effect of menatetrenone on bone mineral density and incidence of vertebral fractures in postmenopausal women with osteoporosis: a comparison with effect of etidronate. J Orthop Sci 6:487-492
6. Fujita T, Orimo H, Inoue T, Kaneda K, Sakurai M, Morita R, Morii H, Yamamoto K, Sugioka Y, Inoue A, Hoshino Y, Kawaguchi H, Yamamoto I, Fukase M, Takaoka K (1993) Double-blind multicenter comparative study with alfacalcidol or etidronate disodium (EHDP) in involutional osteoporosis (in Japanese). Clin Eval 21:261-302
7. Schnur W (1987) Relief of metastatic bone pain with etidronate disodium. Ohio Med 1:62-65
8. Carey PO, Lippert MC (1988) Treatment of painful prostatic bone metastases with oral etidronate disodium. Urology 32:403-407
9. Adami S, Salvagno G, Guarrera G, Bianchi G, Dorizzi R, Rosini R, Mobilio G, Cascio VL (1985) Dichloromethylene-diphosphonate in patients with prostatic carcinoma metastatic to the skeleton. J Urol 134:1152-1154
10. Lorish CD, Maisiak R (1986) The face scale: a brief, nonverbal method for assessing patient mood. Arthritis Rheum 29:906-909
11. Adami S (1997) Bisphosphonates in prostate carcinoma. Cancer 80:1674-1679
12. Paterson CR, Robins SP, Horobin JM, Preece PE, Cuschieri A (1991) Pyridinium crosslinks as markers of bone resorption in patients with breast cancer. Br J Cancer 64:884-886
13. Massidda B, Ionta MT, Foddi MR, Mascia L, Bruder F, Aloi MB, Meledduc C, Giannoni MN (1996) Usefulness of pyridinium crosslinks and CA 15-3 as markers in metastatic bone breast carcinoma. Anticancer Res 16:2221-2224
14. Nguyen-Pamart M, Bonneterre M, Hecquet B (1995) Urinary excretion of deoxypyridinoline in patients with breast cancer. Anticancer Res 15:1601-1603
15. Ikeda I, Miura T, Kondo I (1996) Pyridinoline cross-links as urinary markers of bone metastasis in patients with prostate cancer. Br J Urol 77:102-106
16. Maeda H, Koizumi M, Yoshimura K, Yamauchi T, Kawai T, Ogata E (1997) Correlation between bone metabolic markers and bone scan in prostatic cancer. J Urol 157:539-543
17. Pegler RCM, Hamdy NAT, Zwinderman AH, Lycklama a Nijeholt AA, Papapoulos SE (1998) Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton. Bone 22:403-408
18. Pecherstorfer M, Zimmer-Roth I, Schilling T, Woitge HW, Schmidt H, Baumgartner G, Thiebaud D, Ludwig H, Seibe MJ (1995) The diagnostic value of urinary pyridinium cross-links of collagen, serum total alkaline phosphatase, and urinary calcium excretion in neoplastic bone disease. J Clin Endocrinol Metab 80:97-103
19. Bellahcene A, Menard S, Bufalino R, Moreau L, Castronovo V (1996) Expression of bone sialoprotein in primary human breast cancer is associated with poor survival. Int J Cancer 69:350-353
20. Paterson AHG, Kanis JA, Powles TJ, McCloskey E, Hanson J, Ashley S (1995) Role of bisphosphonates in prevention and treatment of bone metastases from breast cancer. Can J Oncol 5:54-57
21. Fleisch H (2000) Bisphosphonates in Bone Disease. From the Laboratory to the Patients. Academic Press, New York, pp 88-117
22. Ryzen E, Martodam RR, Troxell M, Benson A, Paterson A, Shepard K, Hicks R (1985) Intravenous etidronate in the management of malignant hypercalcemia. Arch Intern Med 145:449-452
23. Kanis JA, Urwin GH, Gray RES, Beneton MNC, McCloskey EV, Hamdy NAT, Murray SA (1987) Effects of intravenous etidronate disodium on skeletal and calcium metabolism. Am J Med 82 (Suppl 2A):55-70
24. Averbuch SD (1993) New bisphosphonates in the treatment of bone metastases. Cancer 72:3443-3452
25. Nielsen OS, Munro AJ, Tannock IF (1991) Bone metastases: pathophysiology and management policy. J Clin Oncol 9:509-524
26. Nishikaku F, Nakayama T, Nakatsuka M (1998) Analgesic property of bisphosphonate, etidronate in animal models (in Japanese). Jpn Pharmacol Ther 26:457-463
27. Tanaka T, Nakayama T, Katsumata T (2001) Etidronate: therapeutic agent for osteoporosis possessing analgesic effect (in Japanese). Bio Clinica 16:57-61